Try our beta test site
14 studies found for:    ALT-803 cancer
Show Display Options
Rank Status Study
1 Not yet recruiting QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: ALT-803 Subcutaneous;   Biological: ALT-803 Intraperitoneal
2 Recruiting QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Condition: Advanced Pancreatic Cancer
Interventions: Biological: Gemcitabine;   Biological: Nab-paclitaxel;   Biological: ALT-803
3 Recruiting A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Biological: ALT-803
4 Recruiting QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Condition: Non-muscle Invasive Bladder Cancer
Interventions: Biological: BCG+ALT-803;   Biological: BCG
5 Not yet recruiting QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: ALT-803;   Drug: BCG
6 Recruiting ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Biological: ALT-803;   Biological: Nivolumab
7 Recruiting IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Conditions: Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndromes (MDS);   Lymphoma;   Myeloma;   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML)
Intervention: Biological: ALT-803
8 Not yet recruiting Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Myeloproliferative Syndromes;   Plasma Cell Myeloma;   Colon Carcinoma;   Adenocarcinoma of Rectum;   Soft Tissue Sarcoma;   Ewing's Sarcoma;   Rhabdomyosarcoma
Interventions: Biological: Natural Killer (NK) Cells;   Biological: ALT803
9 Not yet recruiting QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
Condition: Acute Myeloid Leukemia
Intervention: Biological: ALT-803
10 Recruiting QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Intervention: Biological: ALT-803
11 Not yet recruiting QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT
Conditions: Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention: Drug: ALT-803
12 Recruiting QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Condition: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions: Biological: Rituximab;   Biological: ALT-803
13 Not yet recruiting 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant (ASCT);   Biological: Expanded Natural Killer (ENK) Cells;   Drug: ALT-803
14 Recruiting Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis

Study has passed its completion date and status has not been verified in more than two years.